Skip to main content

Emgality®: a once-monthly preventive treatment for patients with episodic or chronic migraine1

Female migraine patient

Emgality can reduce the impact of migraine during and between attacks1

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine in adults.

See data

Monthly MHD reduction

See data

Impact of migraine on daily activities

See data

Migraine-related disability

See data

Burden in between migraine attacks

INDICATIONS

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the preventive treatment of migraine and the treatment of episodic cluster headache.

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

A patient sitting at her desk at her office job

THE EMGALITY PATIENT - Meet Jessicaa

Migraine continues to impact her work and personal life during and between attacks

  • Experiences 4-14 UNPREDICTABLE MHDs PER MONTH
  • She wants to TAKE CONTROL by finding a different preventive treatment option for her unpredictable migraine
  • Tried therapeutic doses of 2 STANDARD-OF-CARE GENERIC PREVENTIVES

aHypothetical patient profile with episodic migraine.

MHD=migraine headache day.

SELECT IMPORTANT SAFETY INFORMATION

Hypersensitivity Reactions

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

References

  1. Emgality. Prescribing Information. Lilly USA, LLC.

Explore: Migraine Efficacy, Migraine Dosing, or Savings & Support

IMPORTANT SAFETY INFORMATION

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

GZ HCP ISI 14SEP2022

INDICATIONS

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache